Anti-tumor effects of biochemical defense modifier antineoplaston again colorectal cancer
Anti-tumor effects of biochemical defense modifier antineoplaston again colorectal cancer
批准号:
13671364
负责人:
SHIROUZU Kazuo
金额:
$2.56万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
(in vitro study)Antineoplaston AS2-1 inhibited colon cancer cell (KM12SM, SW620, SW1417, Colo206, HCTI16) proliferation in a dosage-and time-dependent manner through G1 cell arrest and induction of apoptosis. AS2-1 up-regulated the protein expression of cyclin D and cyclin E, and down-regulated the protein expression of p-16 and p21, resulting down-regulated the protein level of phosphorylated Rb in KM12SM and HCT116 cells. Five mg/ml of AS2-1 induced apoptosis in tumor cells through down-regulation of XIAP and up-regulation of caspase 3 and caspase 8. Methyl scan DNA chip study revealed that AS2-1 normalized or reduced the hyper methylation in various genes.(in vivo study)AS2-1 inhibited the growth and tumorigenecity of implanted colon tumors (KM121SM, HCT116) into the subcutis in nude mice. AS2-1 showed significant reduction in lung metastasis and prolongation of survival time using removal model of orthotopically implanted colon cancer in nude rats.(Clinical study)We have conducted a randomized control study after hepatectomy in colorectal metastasis to the liver. Hepatic arterial infusion chemotherapy using 5-FU with or without antineoplastons was performed in 64 patients between 1998 and 2004. There was no significant difference in disease-free survival rate between the two groups, however the survival rates in antineoplaston group was tended to be higher than that in the control group. Further follow-up should be necessary to conclude usefulness of antineoplastons.Antineoplastons would be effective in colorectal cancer in particular in adjuvant setting in combination with cytotoxic chemotherapeutic agents.
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
緒方 裕: "大腸癌肝転移に対する肝切除後補助療法としての生化学的抗腫瘍剤アンチネオプラストン投与"臨床と研究. 第78巻・第11号. 2099-2102 (2001)
Yutaka Ogata:“生化抗肿瘤剂抗肿瘤药作为肝切除术后辅助治疗结直肠癌肝转移”,临床与研究,第 78 卷,第 11 期。2099-2102 (2001)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
緒方 裕: "大腸癌肝転移に対する肝切除後補助療法としての生化学的抗腫瘍剤アンチネオプラストン投与"臨床と研究. 78. 2099-2102 (2001)
Yutaka Ogata:“生化抗肿瘤剂抗肿瘤药作为肝切除术后结直肠癌肝转移的辅助治疗”临床与研究78。2099-2102(2001)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ogata Y.: "Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases : report of a case"Surgery Today. (in press). (2003)
Ogata Y.:“用抗肿瘤药治疗患有不可切除的多发性肝转移的结肠癌后的长期生存:病例报告”《今日外科》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
的野 敬子: "生化学的抗腫瘍剤アンチネオプラストンが奏効した大腸癌切除不能多発肝転移の1例"臨床と研究. 80. 373-376 (2003)
Keiko Matono:“一例无法切除的结直肠癌多发性肝转移病例,对生化抗肿瘤药物抗肿瘤药反应良好”《临床与研究》,80. 373-376 (2003)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ogata Y.: "Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases : report of a case"Surgery Today. 448-453 (2003)
Ogata Y.:“用抗肿瘤药治疗患有不可切除的多发性肝转移的结肠癌后的长期生存:病例报告”《今日外科》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 13 条
Significant of newral cell adhesion molecule (NCAM) in rectal cancer. - Special reference to the indication of nerve preserving operation -
-
批准号:05671101
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1993
-
负责人:SHIROUZU Kazuo
-
依托单位: